Cargando…
Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy
INTRODUCTION: Drug delivery systems (DDSs) based on liposomes are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve biosafe, accurate, and efficient cancer therapy of liposomes with single function o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944797/ https://www.ncbi.nlm.nih.gov/pubmed/36844433 http://dx.doi.org/10.2147/IJN.S382109 |
_version_ | 1784891995678834688 |
---|---|
author | Lu, Wangxing Liu, Wenjie Hu, Anna Shen, Jian Yi, Hanxi Cheng, Zeneng |
author_facet | Lu, Wangxing Liu, Wenjie Hu, Anna Shen, Jian Yi, Hanxi Cheng, Zeneng |
author_sort | Lu, Wangxing |
collection | PubMed |
description | INTRODUCTION: Drug delivery systems (DDSs) based on liposomes are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve biosafe, accurate, and efficient cancer therapy of liposomes with single function or single mechanism. To solve this problem, we designed a multifunctional and multimechanism nanoplatform based on polydopamine (PDA)-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT. METHODS: ICG and DOX were co-incorporated in polyethylene glycol modified liposomes, which were further coated with PDA by a facile two-step method to construct PDA-liposome nanoparticles (PDA@Lipo/DOX/ICG). The safety of nanocarriers was investigated on normal HEK-293 cells, and the cellular uptake, intracellular ROS production capacity, and combinatorial treatment effect of the nanoparticles were assessed on human breast cancer cells MDA-MB-231. In vivo biodistribution, thermal imaging, biosafety assessment, and combination therapy effects were estimated based on MDA-MB-231 subcutaneous tumor model. RESULTS: Compared with DOX·HCl and Lipo/DOX/ICG, PDA@Lipo/DOX/ICG showed higher toxicity on MDA-MB-231 cells. After endocytosis by target cells, PDA@Lipo/DOX/ICG produced a large amount of ROS for PDT by 808 nm laser irradiation, and the cell inhibition rate of combination therapy reached up to 80.4%. After the tail vein injection (DOX equivalent of 2.5 mg/kg) in mice bearing MDA-MB-231 tumors, PDA@Lipo/DOX/ICG significantly accumulated at the tumor site at 24 h post injection. After 808 nm laser irradiation (1.0 W/cm(2), 2 min) at this timepoint, PDA@Lipo/DOX/ICG efficiently suppressed the proliferation of MDA-MB-231 cell and even thoroughly ablated tumors. Negligible cardiotoxicity and no treatment-induced side effects were observed. CONCLUSION: PDA@Lipo/DOX/ICG is a multifunctional nanoplatform based on PDA-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT. |
format | Online Article Text |
id | pubmed-9944797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99447972023-02-23 Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy Lu, Wangxing Liu, Wenjie Hu, Anna Shen, Jian Yi, Hanxi Cheng, Zeneng Int J Nanomedicine Original Research INTRODUCTION: Drug delivery systems (DDSs) based on liposomes are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve biosafe, accurate, and efficient cancer therapy of liposomes with single function or single mechanism. To solve this problem, we designed a multifunctional and multimechanism nanoplatform based on polydopamine (PDA)-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT. METHODS: ICG and DOX were co-incorporated in polyethylene glycol modified liposomes, which were further coated with PDA by a facile two-step method to construct PDA-liposome nanoparticles (PDA@Lipo/DOX/ICG). The safety of nanocarriers was investigated on normal HEK-293 cells, and the cellular uptake, intracellular ROS production capacity, and combinatorial treatment effect of the nanoparticles were assessed on human breast cancer cells MDA-MB-231. In vivo biodistribution, thermal imaging, biosafety assessment, and combination therapy effects were estimated based on MDA-MB-231 subcutaneous tumor model. RESULTS: Compared with DOX·HCl and Lipo/DOX/ICG, PDA@Lipo/DOX/ICG showed higher toxicity on MDA-MB-231 cells. After endocytosis by target cells, PDA@Lipo/DOX/ICG produced a large amount of ROS for PDT by 808 nm laser irradiation, and the cell inhibition rate of combination therapy reached up to 80.4%. After the tail vein injection (DOX equivalent of 2.5 mg/kg) in mice bearing MDA-MB-231 tumors, PDA@Lipo/DOX/ICG significantly accumulated at the tumor site at 24 h post injection. After 808 nm laser irradiation (1.0 W/cm(2), 2 min) at this timepoint, PDA@Lipo/DOX/ICG efficiently suppressed the proliferation of MDA-MB-231 cell and even thoroughly ablated tumors. Negligible cardiotoxicity and no treatment-induced side effects were observed. CONCLUSION: PDA@Lipo/DOX/ICG is a multifunctional nanoplatform based on PDA-coated liposomes for accurate and efficient combinatorial cancer therapy of chemotherapy and laser-induced PDT/PTT. Dove 2023-02-17 /pmc/articles/PMC9944797/ /pubmed/36844433 http://dx.doi.org/10.2147/IJN.S382109 Text en © 2023 Lu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lu, Wangxing Liu, Wenjie Hu, Anna Shen, Jian Yi, Hanxi Cheng, Zeneng Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title | Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title_full | Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title_fullStr | Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title_full_unstemmed | Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title_short | Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy |
title_sort | combinatorial polydopamine-liposome nanoformulation as an effective anti-breast cancer therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944797/ https://www.ncbi.nlm.nih.gov/pubmed/36844433 http://dx.doi.org/10.2147/IJN.S382109 |
work_keys_str_mv | AT luwangxing combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy AT liuwenjie combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy AT huanna combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy AT shenjian combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy AT yihanxi combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy AT chengzeneng combinatorialpolydopamineliposomenanoformulationasaneffectiveantibreastcancertherapy |